메스테롤론
메스테롤론 · proviron · mesterolon · MESTERELONE · testiwop · masterolone · sh723 · NSC-7504
식별자 및 물리적 특성
| CAS No. | 1424-00-6 |
|---|---|
| 분자식 | C20H32O2 |
| 평균 분자량 | 304.5 g/mol |
| 단동위원소 질량 | 304.24023026 g/mol |
| SMILES | C[C@H]1CC(=O)C[C@@H]2CC[C@H]3[C@@H]4CC[C@H](O)[C@@]4(C)CC[C@@H]3[C@]21C |
| InChIKey | UXYRZJKIQKRJCF-TZPFWLJSSA-N |
| PubChem CID | 15020 |
| ChEMBL | CHEMBL258918 |
| ChEBI | CHEBI:135293 |
| EC No. | 215-836-3 |
| DTXSID | DTXSID90878533 |
| 현지명 | 메스테롤론 |
화학 및 물리적 성질
| XLogP | 4.1 |
|---|---|
| 극성 표면적 | 37.3 |
| 수소 결합 공여자 수 | 1 |
| 수소 결합 수용자 수 | 2 |
| 회전 가능 결합 수 | 0 |
| 무거운 원자 수 | 22 |
| 형식 전하 | 0 |
| 복잡도 | 486 |
| 녹는점 | 204 °C208 °C |
| Physical Description | Solid |
| 끓는 점 | 420.3±45.0 °C(Predicted) |
| 밀도 | 1.156 g/cm3 |
| 굴절률 | 17.6 ° (C=0.9, CHCl3) |
| 저장 조건 | 2-8°C |
| 용해도 | 물에 거의 녹지 않으며, 아세톤, 에틸 아세테이트 및 메탄올에 조금 녹습니다. |
| pKa(산도 계수) | 15.09±0.70(Predicted) |
| 용해도 | 3mg/L at 20℃ |
| Merck | 5916 |
| 주요 응용 | 법의학 및 독성학의약품(소분자)수의사 |
| InChI | InChI=1/C20H32O2/c1-12-10-14(21)11-13-4-5-15-16-6-7-18(22)19(16,2)9-8-17(15)20(12,13)3/h12-13,15-18,22H,4-11H2,1-3H3/t12-,13-,15-,16-,17-,18-,19-,20-/s3 |
| InChIKey | UXYRZJKIQKRJCF-TZPFWLJSSA-N |
| SMILES | [C@@]12([H])CC[C@@]3([H])CC(=O)C[C@H](C)[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@H](CC[C@@]21[H])O |&1:0,4,10,12,14,18,20,23,r| |
화학적 성질
White or yellowish crystalline powder.
안전 및 규제
| GHS 분류 | WarningH302 (97.5%): Harmful if swallowed [Warning Acute toxicity, oral]H312 (97.5%): Harmful in contact with skin [Warning Acute toxicity, dermal]H332 (97.5%): Harmful if inhaled [Warning Acute toxicity, inhalation]P261, P264, P270, P271, P280, P301+P317, P302+P352, P304+P340, P317, P321, P330, P362+P364, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 40 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. |
|---|---|
| 규제 정보 | DEA schedule III controlled substanceStatus: Active Update: 30-03-2020 https://echa.europa.eu/registration-dossier/-/registered-dossier/12497 |
| Hazard Classes and Categories | Acute Tox. 4 (97.5%) |
| 수질 위해 등급(WGK) | 3 |
| RTECS 번호 | BV8063400 |
| 관세 코드 | 29372900 |
| 위험 문구(R) | 20/21/22-38-19-11-61-60 |
| 위험 표시 | Xn,T,F |
| 안전 문구(S) | 22-24/25-36/37/39-45-53 |
| 위험 등급 | Aquatic Chronic 2Carc. 2Lact.Repr. 1B |
| 저장 분류 | 6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects |
| DEA Controlled Substances | CSCN: 4000CSA SCH: Schedule IIINARC: No |
용도
개요
Mesterolone (Item No. 21171) is an analytical reference standard categorized as an anabolic androgenic steroid. Formulations containing mesterolone have been used in patients with low testosterone or symptoms of aging male syndrome. Mesterolone cannot be aromatized to estrogens, unlike other androgens. This compound is the active ingredient in different pharmaceutical preparations that have been used medically but have also been widely applied in sports in order to improve athlete performance. Mesterolone is regulated as a Schedule III drug in the United States. This product is intended for research and forensic applications.
용도
Mesterolone is a synthetic androgen and a dihydrotestosterone derivative. Mesterolone is rarely used for replacement therapies due to its weak androgenic activity.
일반 설명
Mesterolone is a synthetic anabolic-androgenic steroid (AAS) and derivative of dihydrotestosterone (DHT). It is inactivated by 3α-hydroxysteroid dehydrogenase in skeleta muscules so it is considered a weak androgen. It is not a substrate for aromatase so it is not converted into estrogen. Mesterolone demonstrated to have minimal effect on sperm counts and levels of FSH or LH. Experiments of mesterolone serving as a potential treatment of depression are still undergoing.